Last updated: July 17, 2026

Application No. 18/072,959

INTERLEUKIN-21 MUTEIN/ ANTI-PD-1 ANTIBODY CONJUGATES

Non-Final OA

Filed

Dec 01, 2022

Priority

Aug 03, 2017 — provisional 62/540,692 +2 more

Examiner

ABBAS, SYED JARAR

Art Unit

1674

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Amgen Inc.

OA Round

1 (Non-Final)

Examiner Intelligence

ABBAS, SYED JARAR View full profile →

Grants only 0% of cases

Career Allowance Rate

0 granted / 0 resolved

-60.0% vs TC avg

Minimal +0% lift

Without

With

+0.0%

Interview Lift

resolved cases with interview

Typical timeline

Avg Prosecution

33 currently pending

Career history

Total Applications

across all art units

Statute-Specific Performance

§101

1.5%

-38.5% vs TC avg

§103

38.2%

-1.8% vs TC avg

§102

7.4%

-32.6% vs TC avg

§112

22.1%

-17.9% vs TC avg

Black line = Tech Center average estimate • Based on career data from 0 resolved cases

Prosecution Timeline

Dec 01, 2022

Application Filed

Jun 03, 2026

Non-Final Rejection mailed (current)

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

Grant Probability

Low

PTA Risk

Based on 0 resolved cases by this examiner. Grant probability derived from career allowance rate.